drugset
Drugs / SHR3680
last change Dec 2025 re-read 3 minutes ago

SHR3680

targets AR via inhibition

Developed for
castration-resistant prostate carcinoma · prostate cancer · metastatic prostate carcinoma · triple-negative breast carcinoma · breast cancer · hormone-resistant prostate carcinoma · metastatic malignant neoplasm · salivary gland carcinoma
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Fudan University · Atridia Pty Ltd.

Trials 16

today NCT05924256 · Ph 2 NCT05928780 · Ph 1/2 NCT05607693 · Ph 1 NCT05009290 · Ph 3 NCT04631549 · Ph 1 NCT04621669 · Ph 1 NCT04903158 · Ph 1 NCT04603833 · Ph 2 NCT04676035 · Ph 1 NCT04664725 · Ph 1 NCT04355858 · Ph 2 NCT04102124 · Ph 2 NCT03741712 · Ph 1/2 NCT03805399 · Ph 1/2 NCT02747342 · Ph 1 NCT02691975 · Ph 1/2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT05607693 Apr 2023 → Nov 2024 castration-resistant prostate carcinoma Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04631549 Feb 2021 → Jul 2023 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04621669 Jan → Sep 2021 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04903158 Jan → Mar 2021 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04676035 Jun 2020 → Jan 2022 prostate cancer Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04664725 Jun 2020 → Jan 2021 prostate cancer Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02747342 Sep 2016 → Jun 2019 prostate cancer Atridia Pty Ltd. Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT05928780 Jul 2023 → Mar 2024 triple-negative breast carcinoma Fudan University Unknown No outcome recorded
Phase 1/2 NCT03741712 Nov 2018 → Sep 2019 castration-resistant prostate carcinoma Jiangsu HengRui Medicine Co., Ltd. Terminated No outcome recorded
Phase 1/2 NCT03805399 Oct 2018 → Dec 2022 triple-negative breast carcinoma Fudan University Unknown No outcome recorded
Phase 1/2 NCT02691975 Apr 2016 → Dec 2020 hormone-resistant prostate carcinoma, metastatic prostate carcinoma Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 24 trials
Phase 2 NCT05924256 Jul 2023 → Dec 2026 expected salivary gland carcinoma Fudan University Active not recruiting No outcome recorded
Phase 2 NCT04603833 Dec 2020 → Oct 2022 metastatic prostate carcinoma Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 2 NCT04355858 May 2020 → May 2023 breast cancer, metastatic malignant neoplasm Fudan University Unknown No outcome recorded
Phase 2 NCT04102124 Apr 2019 → Aug 2021 castration-resistant prostate carcinoma Jiangsu HengRui Medicine Co., Ltd. Terminated No outcome recorded Stop: Business
Phase 31 trial
Phase 3 NCT05009290 Nov 2021 → Sep 2024 — Jiangsu HengRui Medicine Co., Ltd. Terminated No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT07230106 Background Dec 2025 → Dec 2028 expected prostate cancer Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as SHR 3680 “AR inhibitor SHR3680 240mg qd continuously” NCT03805399 ↗
16

NCT05924256 ↗

NCT04631549 ↗

NCT04621669 ↗

NCT05009290 ↗

NCT04603833 ↗

NCT02747342 ↗

NCT05928780 ↗

NCT03741712 ↗

NCT05607693 ↗

NCT04664725 ↗

Show 6 more sources
Action Inhibit “SHR3680 is a novel strong AR antagonist.” NCT02691975 ↗
Route Oral “SHR3680 is administrated orally” NCT02691975 ↗
Target AR “SHR3680 is a novel strong AR antagonist.” NCT02691975 ↗